Cargando…
Addressing the ‘hypoxia paradox’ in severe COVID-19: literature review and report of four cases treated with erythropoietin analogues
BACKGROUND: Since fall 2019, SARS-CoV-2 spread world-wide, causing a major pandemic with estimated ~ 220 million subjects affected as of September 2021. Severe COVID-19 is associated with multiple organ failure, particularly of lung and kidney, but also grave neuropsychiatric manifestations. Overall...
Autores principales: | Begemann, Martin, Gross, Oliver, Wincewicz, Dominik, Hardeland, Rüdiger, Daguano Gastaldi, Vinicius, Vieta, Eduard, Weissenborn, Karin, Miskowiak, Kamilla W., Moerer, Onnen, Ehrenreich, Hannelore |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474703/ https://www.ncbi.nlm.nih.gov/pubmed/34565332 http://dx.doi.org/10.1186/s10020-021-00381-5 |
Ejemplares similares
-
Erythropoietin as candidate for supportive treatment of severe COVID-19
por: Ehrenreich, Hannelore, et al.
Publicado: (2020) -
T81. MULTIPLE DRUG USE IN SCHIZOPHRENIA - THE ROLE OF EARLY ENVIRONMENTAL RISK ACCUMULATION AND GENETIC PREDISPOSITION
por: Steixner-Kumar, Agnes, et al.
Publicado: (2020) -
Preadult polytoxicomania—strong environmental underpinnings and first genetic hints
por: Steixner-Kumar, Agnes A., et al.
Publicado: (2021) -
Erythropoietin re-wires cognition-associated transcriptional networks
por: Singh, Manvendra, et al.
Publicado: (2023) -
Effects of erythropoietin on depressive symptoms and neurocognitive deficits in depression and bipolar disorder
por: Miskowiak, Kamilla W, et al.
Publicado: (2010)